CoChat
Sign Up
Cited by 12

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Physiologic expansion of human heart-derived cells enhances therapeutic repair of injured myocardium

Mount, Seth, Kanda, Pushpinder, Parent, Sandrine, Khan, Saad, Michie, Connor, Davila, Liliana, Chan, Vincent, Davies, Ross A., Haddad, Haissam, Courtman, David, Stewart, Duncan J., Davis, Darryl R.·2019·Stem Cell Research & Therapy
DOI 10.1186/s13287-019-1418-3PMC PMC6829847
Open this paper in CoChat — free account

Abstract

Background: Serum-free xenogen-free defined media and continuous controlled physiological cell culture conditions have been developed for stem cell therapeutics, but the effect of these conditions on the relative potency of the cell product is unknown. As such, we conducted a head-to-head comparison of cell culture conditions on human heart explant-derived cells using established in vitro measures of cell potency and in vivo functional repair. Methods: Heart explant-derived cells cultured from human atrial or ventricular biopsies within a serum-free xenogen-free media and a continuous physiological culture environment were compared to cells cultured under traditional (high serum) cell culture conditions in a standard clean room facility. Results: Transitioning from traditional high serum cell culture conditions to serum-free xenogen-free conditions had no effect on cell culture yields but provided a smaller, more homogenous, cell product with only minor antigenic changes. Culture within continuous physiologic conditions markedly boosted cell proliferation while increasing the expression of stem cell-related antigens and ability of cells to stimulate angiogenesis. Intramyocardial injection of physiologic cultured cells into immunodeficient mice 1 week after coronary ligation translated into improved cardiac function and reduced scar burden which was attributable to increased production of pro-healing cytokines, extracellular vesicles, and microRNAs. Conclusions: Continuous physiological cell culture increased cell growth, paracrine output, and treatment outcomes to provide the greatest functional benefit after experimental myocardial infarction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-019-1418-3

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study outline. a Schematic contrasting cell culture within a standard clean room environment (STD env) with an isolated facility that continually maintains normal cardiac physiological conditions (37 °C, 80% relative humidity (rh), and 5% oxygen (O2)). b Schematic outlining human atrial and ventricular tissue processing compared throughout the study and key outcomes
Fig. 1 Study outline. a Schematic contrasting cell culture within a standard clean room environment (STD env) with an isolated facility that continually maintains normal cardiac physiological conditions (37 °C, 80% relative humidity (rh), and 5% oxygen (O2)). b Schematic outlining human atrial and ventricular tissue processing compared throughout the study and key outcomesCC BY · PubMed Central
Fig. 2 Effects of serum-free good manufacturing practices (GMP) compatible culture conditions on explant-derived cell (EDC) phenotype. Representative brightfield images of plated cardiac tissue fragments and EDC outgrowth under 20% serum conditions. a 1 day post-plating. b 3 days post-plating. c 7 days post-plating. Representative brightfield images of plated cardiac tissue fragments and EDC outgrowth under serum-free conditions. d 1 day post-plating. e 3 days post-plating. f 7 days post-plating. g Flow cytometry demonstrating that cells cultured in SF STD env conditions were smaller and more homogenous than cells cultured in serum STD env conditions. h Immunohistochemical staining for the cell cycle-associated protein Ki67 in conjunction with DAPI (left panel). Senescence-associated beta-galactosidase+ (β-Gal+) EDCs identified under phase-contrast microscopy by the presence of intracellular hydrolyzed X-galactosidase (right panel). i, j Flow cytometry analysis of phenotypic composition of EDCs. k Effect of cell culture conditions on the ability of EDCs to stimulate human umbilical vein endothelial cells (HUVECs) tubule formation (left panel) or attract circulating angiogenic cells (CACs) across a transwell membrane (right panel; expressed as fold change number of migrated cells compared to basal media containing 100 ng vascular endothelial growth hormone (VEGF; normalization control)). *p ≤ 0.05, **p ≤ 0.01, n = 4 to 5 cell cultures per group. abcg2, ATP-binding cassette sub-family G member 2; cad11, Cadherin-11; DDR2, discoidin domain receptor tyrosine kinase 2; Lin, hematological lineage cocktail; PDGFR, platelet-derived growth factor receptor; SSEA-1, stage-specific embryonic antigen-1
Fig. 2 Effects of serum-free good manufacturing practices (GMP) compatible culture conditions on explant-derived cell (EDC) phenotype. Representative brightfield images of plated cardiac tissue fragments and EDC outgrowth under 20% serum conditions. a 1 day post-plating. b 3 days post-plating. c 7 days post-plating. Representative brightfield images of plated cardiac tissue fragments and EDC outgrowth under serum-free conditions. d 1 day post-plating. e 3 days post-plating. f 7 days post-plating. g Flow cytometry demonstrating that cells cultured in SF STD env conditions were smaller and more homogenous than cells cultured in serum STD env conditions. h Immunohistochemical staining for the cell cycle-associated protein Ki67 in conjunction with DAPI (left panel). Senescence-associated beta-galactosidase+ (β-Gal+) EDCs identified under phase-contrast microscopy by the presence of intracellular hydrolyzed X-galactosidase (right panel). i, j Flow cytometry analysis of phenotypic composition of EDCs. k Effect of cell culture conditions on the ability of EDCs to stimulate human umbilical vein endothelial cells (HUVECs) tubule formation (left panel) or attract circulating angiogenic cells (CACs) across a transwell membrane (right panel; expressed as fold change number of migrated cells compared to basal media containing 100 ng vascular endothelial growth hormone (VEGF; normalization control)). *p ≤ 0.05, **p ≤ 0.01, n = 4 to 5 cell cultures per group. abcg2, ATP-binding cassette sub-family G member 2; cad11, Cadherin-11; DDR2, discoidin domain receptor tyrosine kinase 2; Lin, hematological lineage cocktail; PDGFR, platelet-derived growth factor receptor; SSEA-1, stage-specific embryonic antigen-1CC BY · PubMed Central
Fig. 3 Influence of physiological environment cell culture conditions on explant-derived cell (EDC) culture. a Representative images of plated tissue from two initial cell cultures (UOHI01 and UOHI02) demonstrating progressive spontaneous migration of EDCs from the plated tissue to cover the cultureware over 9 days in culture. b Table outlining the cell yields and viability of the initial three cell cultures demonstrating the impact of reducing the interval between cell culture harvests. c Representative images from the initial cell cultures attempted showing sparse EDC outgrowth after the initial enzymatic harvest and the formation of adherent monolayers that occurred over time. d Experimental schemata, representative images, and experimental outcomes demonstrating the influence of altering cell culture conditions on EDC yields after the first enzymatic digestion. SF, serum free
Fig. 3 Influence of physiological environment cell culture conditions on explant-derived cell (EDC) culture. a Representative images of plated tissue from two initial cell cultures (UOHI01 and UOHI02) demonstrating progressive spontaneous migration of EDCs from the plated tissue to cover the cultureware over 9 days in culture. b Table outlining the cell yields and viability of the initial three cell cultures demonstrating the impact of reducing the interval between cell culture harvests. c Representative images from the initial cell cultures attempted showing sparse EDC outgrowth after the initial enzymatic harvest and the formation of adherent monolayers that occurred over time. d Experimental schemata, representative images, and experimental outcomes demonstrating the influence of altering cell culture conditions on EDC yields after the first enzymatic digestion. SF, serum freeCC BY · PubMed Central
Fig. 4 Influence of culture conditions on heart explant-derived cell (EDC) mediated repair of injured myocardium. a Schemata of the experimental protocol demonstrating echocardiographic-guided intramyocardial injection of 100,000 EDCs into immunodeficient non-obese diabetic severed combined immunodeficient mice 1 week after left coronary artery (LCA) ligation. EDCs cultured using standard serum media in standard cell culture conditions (Serum STD env), serum-free media in STD cell culture conditions (SF STD env), serum-free media-derived EDCs expanded for 1 week in STD cell culture conditions (exSF STD env), and SF media expanded EDCs cultured entirely within continuous physiologic controlled (exSF Phys Env) culture conditions were compared. b Effects of EDC transplant on echocardiographic ejection fraction 3 weeks after cell injection. n = 10 to 13 per group. c EDC engraftment 3 weeks after intramyocardial injection as determined using quantitative polymerase chain reaction analysis for retained human alu sequences (left panel; n = 6 per group) or random field counts of human nuclear antigen+ (HNA+)/4′,6-diamidino-2-phenylindole+ (DAPI+) cells (right panel; n = 8 per group). d Effects of EDC transplant on vessel density (isolectin B4+) within the peri-infarct region. n = 5 per group. e Effects of EDCs on the overall percentage infarcted myocardium (left panel; n = 5 per group) and percentage of viable myocardium within the infarct zone (right panel; n = 6 per group) as determined from Masson’s trichrome staining. *p ≤ 0.05. LCA, left coronary artery; NOD-SCID, non-obese diabetic severe combined immunodeficient; qPCR, quantitative polymerase chain reaction
Fig. 4 Influence of culture conditions on heart explant-derived cell (EDC) mediated repair of injured myocardium. a Schemata of the experimental protocol demonstrating echocardiographic-guided intramyocardial injection of 100,000 EDCs into immunodeficient non-obese diabetic severed combined immunodeficient mice 1 week after left coronary artery (LCA) ligation. EDCs cultured using standard serum media in standard cell culture conditions (Serum STD env), serum-free media in STD cell culture conditions (SF STD env), serum-free media-derived EDCs expanded for 1 week in STD cell culture conditions (exSF STD env), and SF media expanded EDCs cultured entirely within continuous physiologic controlled (exSF Phys Env) culture conditions were compared. b Effects of EDC transplant on echocardiographic ejection fraction 3 weeks after cell injection. n = 10 to 13 per group. c EDC engraftment 3 weeks after intramyocardial injection as determined using quantitative polymerase chain reaction analysis for retained human alu sequences (left panel; n = 6 per group) or random field counts of human nuclear antigen+ (HNA+)/4′,6-diamidino-2-phenylindole+ (DAPI+) cells (right panel; n = 8 per group). d Effects of EDC transplant on vessel density (isolectin B4+) within the peri-infarct region. n = 5 per group. e Effects of EDCs on the overall percentage infarcted myocardium (left panel; n = 5 per group) and percentage of viable myocardium within the infarct zone (right panel; n = 6 per group) as determined from Masson’s trichrome staining. *p ≤ 0.05. LCA, left coronary artery; NOD-SCID, non-obese diabetic severe combined immunodeficient; qPCR, quantitative polymerase chain reactionCC BY · PubMed Central
Fig. 5 Influence of serum free culture conditions on the paracrine signature of explant-derived cells (EDCs). a Select cytokines from an unbiased protein array profiling cytokine content within EDC conditioned media under hypoxic (1% oxygen) basal media conditions. *p < 0.05 vs. media conditioned by EDCs cultured within standard (STD) cell conditions. n=4 per group. b Select cytokines from an unbiased proteome array showing differential expression within media conditioned by STD EDCs and exSF Phys Env EDCs. *p < 0.05 vs. media conditioned by EDCs cultured within standard (STD) cell conditions. n=4 per group. c Effect of cell culture conditions on extracellular vesicle concentration and size. *p < 0.05 vs. all. N=3-4 per group. d Up and downregulated miRNAs in EVs isolated from exSF Phys Env EDCs compared to serum STD EDCs. n=3. FGF basic: Fibroblast growth factor basic; Flt-3: tyrosine kinase 3; GM-CSF: Granulocyte-macrophage colony-stimulating factor; HGF: Hepatocyte growth factor; ICAM: Intercellular adhesion molecule; IGFBP: Insulin-like growth factor binding protein; IL: interleukin; OPG: Osteoprotegerin; PDGF: Platelet-derived growth factor; SDF-1α: stromal cell-derived factor 1 alpha; uPAR: urokinase-type plasminogen activator; VEGF: Vascular endothelial growth hormone
Fig. 5 Influence of serum free culture conditions on the paracrine signature of explant-derived cells (EDCs). a Select cytokines from an unbiased protein array profiling cytokine content within EDC conditioned media under hypoxic (1% oxygen) basal media conditions. *p < 0.05 vs. media conditioned by EDCs cultured within standard (STD) cell conditions. n=4 per group. b Select cytokines from an unbiased proteome array showing differential expression within media conditioned by STD EDCs and exSF Phys Env EDCs. *p < 0.05 vs. media conditioned by EDCs cultured within standard (STD) cell conditions. n=4 per group. c Effect of cell culture conditions on extracellular vesicle concentration and size. *p < 0.05 vs. all. N=3-4 per group. d Up and downregulated miRNAs in EVs isolated from exSF Phys Env EDCs compared to serum STD EDCs. n=3. FGF basic: Fibroblast growth factor basic; Flt-3: tyrosine kinase 3; GM-CSF: Granulocyte-macrophage colony-stimulating factor; HGF: Hepatocyte growth factor; ICAM: Intercellular adhesion molecule; IGFBP: Insulin-like growth factor binding protein; IL: interleukin; OPG: Osteoprotegerin; PDGF: Platelet-derived growth factor; SDF-1α: stromal cell-derived factor 1 alpha; uPAR: urokinase-type plasminogen activator; VEGF: Vascular endothelial growth hormoneCC BY · PubMed Central
Fig. 6 The rationale for autologous heart-derived cell therapy. a Schematic comparison of traditional centralized cell manufacturing with the decentralized cytocentric strategy afforded through modular physiologic GMP serum-free cell culture. b Conceptual promise of all cell therapies (blue line) to restore function and prolong survival contrasted with the dismal prognosis conferred after first hospitalization for heart failure. c Schematic outline of the real world effect of heart failure on physical function ranging between excellent and death (ordinate) as a function of time (abscissa) from cardiac injury. The influence of early medical therapy and progressive functional decline is contrasted between young (black line) and aged (gray line) patients. The ability of autologous heart-derived cell therapy (blue line) to partially restore function is shown which results in a functional deficit that for an elderly patient is not very much different from baseline. Figure modified from Goodlin with permission [43]
Fig. 6 The rationale for autologous heart-derived cell therapy. a Schematic comparison of traditional centralized cell manufacturing with the decentralized cytocentric strategy afforded through modular physiologic GMP serum-free cell culture. b Conceptual promise of all cell therapies (blue line) to restore function and prolong survival contrasted with the dismal prognosis conferred after first hospitalization for heart failure. c Schematic outline of the real world effect of heart failure on physical function ranging between excellent and death (ordinate) as a function of time (abscissa) from cardiac injury. The influence of early medical therapy and progressive functional decline is contrasted between young (black line) and aged (gray line) patients. The ability of autologous heart-derived cell therapy (blue line) to partially restore function is shown which results in a functional deficit that for an elderly patient is not very much different from baseline. Figure modified from Goodlin with permission [43]CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 55

  1. Alter DA, Ko DT, Tu JV, Stukel TA, Lee DS, Laupacis A, et al. The average lifespan of patients discharged from hospital with heart failure. J Gen Intern Med. 2012;27(9):1171–9. · DOI
  2. Lee DS, Schull MJ, Alter DA, Austin PC, Laupacis A, Chong A, et al. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail. 2010;3(2):228–35. · DOI
  3. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63(2):110–22. · DOI
  4. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895–904. · DOI
  5. Ishigami S, Ohtsuki S, Eitoku T, Ousaka D, Kondo M, Kurita Y, et al. Intracoronary cardiac progenitor cells in single ventricle physiology: the PERSEUS (cardiac progenitor cell infusion to treat univentricular heart disease) randomized phase 2 trial. Circ Res. 2017;120(7):1162–73. · DOI
  6. Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015;116(4):653–64. · DOI
  7. Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, et al. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg. 2015;150(5):1198–207 208 e1–2. · DOI
  8. Davis DR. Heart stem cells in the post-Anversa era. Eur Heart J. 2019;40(13):1039–41. · DOI
  9. Davis DR, Kizana E, Terrovitis J, Barth AS, Zhang Y, Smith RR, et al. Isolation and expansion of functionally-competent cardiac progenitor cells directly from heart biopsies. JMCC. 2010;49(2):312–21.
  10. Chimenti I, Gaetani R, Forte E, Angelini F, De FE, Zoccai GB, et al. Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture. J Cell Mol Med. 2014;18(4):624–34. · DOI
  11. Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014;14(2):141–5. · DOI
  12. Shenje LT, Field LJ, Pritchard CA, Guerin CJ, Rubart M, Soonpaa MH, et al. Lineage tracing of cardiac explant derived cells. PLoS One. 2008;3(4):e1929. · DOI
  13. Andersen DC, Andersen P, Schneider M, Jensen HB, Sheikh SP. Murine “Cardiospheres” are not a source of stem cells with cardiomyogenic potential. Stem Cells. 2009;27(7):1571–81. · DOI
  14. Jochems CE, van der Valk JB, Stafleu FR, Baumans V. The use of fetal bovine serum: ethical or scientific problem? Altern Lab Anim. 2002;30(2):219–27. · DOI · Paper page
  15. Li TS, Cheng K, Malliaras K, Matsushita N, Sun B, Marban L, et al. Expansion of human cardiac stem cells in physiological oxygen improves cell production efficiency and potency for myocardial repair. Cardiovasc Res. 2011;89(1):157–65. · DOI
  16. Li TS, Cheng K, Malliaras K, Matsushita N, Sun B, Marban L, et al. Expansion of human cardiac stem cells in physiological oxygen improves cell production efficiency and potency for myocardial repair. Cardiovasc Res. 2011;89(1):157–65. · DOI
  17. Neutelings T, Lambert CA, Nusgens BV, Colige AC. Effects of mild cold shock (25 degrees C) followed by warming up at 37 degrees C on the cellular stress response. PLoS One. 2013;8(7):e69687. · DOI
  18. Galluzzi L, Yamazaki T, Kroemer G. Linking cellular stress responses to systemic homeostasis. Nat Rev Mol Cell Biol. 2018;19(11):731–45. · DOI
  19. Tilokee EL, Latham N, Jackson R, Mayfield AE, Ye B, Mount S, et al. Paracrine engineering of human explant-derived cardiac stem cells to over-express stromal-cell derived factor 1alpha enhances myocardial repair. Stem Cells. 2016;34(7):1826–35. · DOI
  20. Mayfield AE, Fitzpatrick ME, Latham N, Tilokee EL, Villanueva M, Mount S, et al. The impact of patient co-morbidities on the regenerative capacity of cardiac explant-derived stem cells. Stem Cell Res Ther. 2016;7(1):60. · DOI
  21. Jackson R, Tilokee EL, Latham N, Mount S, Rafatian G, Strydhorst J, et al. Paracrine engineering of human cardiac stem cells with insulin-like growth factor 1 enhances myocardial repair. J Am Heart Assoc. 2015;4(9):e002104. · DOI
  22. Mayfield AE, Tilokee EL, Latham N, McNeill B, Lam BK, Ruel M, et al. The effect of encapsulation of cardiac stem cells within matrix-enriched hydrogel capsules on cell survival, post-ischemic cell retention and cardiac function. Biomaterials. 2014;35(1):133–42. · DOI
  23. Molgat AS, Tilokee EL, Rafatian G, Vulesevic B, Ruel M, Milne R, et al. Hyperglycemia inhibits cardiac stem cell-mediated cardiac repair and angiogenic capacity. Circulation. 2014;130(11 Suppl 1):S70–S6. · DOI
  24. Latham N, Ye B, Jackson R, Lam B, Kuraitis D, Ruel M, et al. Human blood and cardiac stem cells synergize to enhance cardiac repair when cotransplanted into ischemic myocardium. Circulation. 2013;128(suppl1):S1–8.
  25. Ott HC, Matthiesen TS, Brechtken J, Grindle S, Goh SK, Nelson W, et al. The adult human heart as a source for stem cells: repair strategies with embryonic-like progenitor cells. Nat Clin Pract Cardiovasc Med. 2007;4(S1):S27–39. · DOI
  26. Kanda P, Alarcon EI, Yeuchyk T, Parent S, de Kemp RA, Variola F, et al. Deterministic encapsulation of human cardiac stem cells in variable composition nanoporous gel cocoons to enhance therapeutic repair of injured myocardium. ACS Nano. 2018;12(5):4338–50. · DOI
  27. Jackson R, Mount S, Ye B, Mayfield AE, Chan V, Boodhwani M, et al. Isolation of human explant derived cardiac stem cells from cryopreserved heart tissue. PLoS One. 2017;12(4):e0176000. · DOI
  28. Mayfield AE, Kanda P, Nantsios A, Parent S, Mount S, Dixit S, et al. Interleukin-6 mediates post-infarct repair by cardiac explant-derived stem cells. Theranostics. 2017;7(19):4850–61. · DOI
  29. Ibrahim AG, Cheng K, Marban E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014;2(5):606–19. · DOI
  30. van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–28. · DOI · Paper page
  31. Lesizza P, Prosdocimo G, Martinelli V, Sinagra G, Zacchigna S, Giacca M. Single-dose Intracardiac injection of pro-regenerative micrornas improves cardiac function after myocardial infarction. Circ Res. 2017;120(8):1298–304. · DOI
  32. Xu J, Tang Y, Bei Y, Ding S, Che L, Yao J, et al. MiR-19b attenuates H2O2-induced apoptosis in rat H9C2 cardiomyocytes via targeting PTEN. Oncotarget. 2016;7(10):10870–8. · DOI
  33. Gao F, Kataoka M, Liu N, Liang T, Huang Z-P, Gu F, et al. Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction. Nat Commun. 2019;10(1):1802. · DOI
  34. Raso A, Dirkx E, Philippen LE, Fernandez-Celis A, De Majo F, Sampaio-Pinto V, et al. Therapeutic delivery of miR-148a suppresses ventricular dilation in heart failure. Mol Ther. 2019;27(3):584–99. · DOI
  35. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of micrornas after myocardial infarction reveals a role of Mir-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105(35):13027–32. · DOI
  36. Li Q, Xie J, Wang B, Li R, Bai J, Ding L, et al. Overexpression of microRNA-99a attenuates cardiac hypertrophy. PLoS One. 2016;11(2):e0148480. · DOI
  37. Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A, et al. Human cardiac stem cells. Proc Natl Acad Sci U S A. 2007;104(35):14068–73. · DOI
  38. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115:896–908. · DOI
  39. Sebastiao MJ, Menta R, Serra M, Palacios I, Alves PM, Sanchez B, et al. Human cardiac stem cells inhibit lymphocyte proliferation through paracrine mechanisms that correlate with indoleamine 2,3-dioxygenase induction and activity. Stem Cell Res Ther. 2018;9(1):290. · DOI
  40. Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol. 2009;54(5):386–96. · DOI
  41. Capricor Therapeutics Provides Update on ALLSTAR Trial [press release]. May 12, 2017. 2017. https://www.prnewswire.com/news-releases/capricor-therapeutics-provides-update-on-allstar-trial-300456715.html .
  42. Rafatian G, Davis DR. Heart-derived cell therapy 2.0: paracrine strategies to increase therapeutic repair of injured myocardium. Stem Cells. 2018;36(12):1794–803. · DOI
  43. Mount S, Davis DR. Electrical effects of stem cell transplantation for ischaemic cardiomyopathy: friend or foe? J Physiol. 2016;594(9):2511–24. · DOI
  44. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94(11):2807–16. · DOI · Paper page
  45. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–55. · DOI · Paper page
  46. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994;90(4):1765–73. https://www.ahajournals.org/doi/abs/10.1161/01.CIR.90.4.1765 . · DOI
  47. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992;86(2):431–8. · DOI
  48. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91(10):2573–81. · DOI
  49. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319(2):80–6. · DOI
  50. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40(5):970–5. · DOI
  51. Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation. 2006;113(2):266–72. · DOI
  52. St John Sutton M, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009;120(19):1858–65. · DOI
  53. Wikstrom G, Blomstrom-Lundqvist C, Andren B, Lonnerholm S, Blomstrom P, Freemantle N, et al. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J. 2009;30(7):782–8. · DOI
  54. Barsheshet A, Goldenberg I, Moss AJ, Eldar M, Huang DT, McNitt S, et al. Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur Heart J. 2011;32(13):1622–30. · DOI
  55. Vigneault P, Naud P, Qi X, Xiao J, Villeneuve L, Davis DR, et al. Calcium-dependent potassium channels control proliferation of cardiac progenitor cells and bone marrow-derived mesenchymal stem cells. J Physiol. 2018;596(12):2359–79. · DOI

Cited by

Sorted by citations

See all 12

Metadata

Authors
Mount, S., Kanda, P., Parent, S., Khan, S., Michie, C., Davila, L., Chan, V., Davies, R. A., Haddad, H., Courtman, D., Stewart, D. J., & Davis, D. R.
ORCID
Davis, Darryl R.
Venue
Stem Cell Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2019-11-04
Volume
10
Issue
1
ISSN
1757-6512
DOI
10.1186/s13287-019-1418-3
PMC
PMC6829847
Cited by
12
References
4
Language
en
Licence
Funders
  • Canadian Institutes of Health Research (PJT-162088, MC2-121291, Frederick Banting and Charles Best Canada Graduate Scholarship)
  • Stem Cell Network (NA)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review